Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Biopharm Stat. 2017 Nov 27;28(2):320–332. doi: 10.1080/10543406.2017.1397012

Figure 3.

Figure 3

Simulation results for using the analytical assessment evidence in both designing and analyzing the Phase 3 study: (a) and (c) show the ratio of the sample sizes in the Phase 3 study to achieve the power of 80% when the prior evidence is used versus when it is not used; and (b) and (d) show the power of the proposed equivalence test in analyzing the Phase 3 data.